RxDoctor Payments Data

William Collazo

Cardiovascular Disease · Oklahoma City, OKNPI 1649290594

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,299 of the $11,381 with a category attached, or 72.9%. Abbott accounts for 72.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $4,139 and has fallen 87.0% since, to $537 in 2025.

$11,381in general payments, 2019–2025

Across 159 payments — averaging $71.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Medtronic$1K
  • Boston Scientific$975
  • Abiomed$430
  • Shockwave Medical, Inc$254
  • Amgen$157
  • plus $259 from 3 others

What the payments were for

  • Travel & lodging$3,06527%
  • Food & beverage$8,29973%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott114$8,245
Medtronic(2 entities)22$1,060
Boston Scientific6$975
Abiomed5$430
Shockwave Medical, Inc2$254
Amgen3$157
E.r. Squibb & Sons, L.L.C.2$150
Penumbra, Inc.2$68
Chiesi USA, Inc.3$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,381 in reported general payments places this provider in the 85th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$194,725
Medicare patients
672
Services billed
3,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$146,417
Repatha SureclickEvolocumab90$67,255
XareltoRivaroxaban43$46,242
BrilintaTicagrelor56$46,001
EntrestoSacubitril/Valsartan29$32,829
Repatha SyringeEvolocumab36$28,904
Ezetimibe326$16,328
FarxigaDapagliflozin Propanediol12$12,442
Atorvastatin Calcium476$10,493
Metoprolol Succinate428$7,154
Losartan Potassium310$3,669
ClopidogrelClopidogrel Bisulfate260$3,184
Omega-3 Acid Ethyl Esters45$2,598
Isosorbide Mononitrate ErIsosorbide Mononitrate165$2,456
Rosuvastatin Calcium94$1,748

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →